Key result
The modified Cardiometabolic Disease Staging System predicted 10-year risk of major adverse cardiovascular events, performing superiorly to the Framingham risk score and comparably to the ACC/AHA pooled cohort equations.
Why the study?
Does the modified Cardiometabolic Disease Staging System (CMDS) improve prediction of 10-year risk of major adverse cardiovascular events compared to traditional risk models in U.S. adults?
Does the modified Cardiometabolic Disease Staging System (CMDS) improve prediction of 10-year risk of major adverse cardiovascular events compared to traditional risk models in U.S. adults?
The modified Cardiometabolic Disease Staging System offers a comprehensive risk prediction tool that incorporates cardiometabolic markers to identify patients at high risk for major adverse cardiovascular events, guiding earlier preventative care.
[Figure: see text]
No takes yet. Share an insight, caveat, or question.
Singh et al. (2024) conducted an editorial in Cardiometabolic Risk and Cardiovascular Disease (n=48,000). Modified Cardiometabolic Disease Staging System (CMDS) vs. Framingham risk score and ACC/AHA pooled cohort equations was evaluated on 10-year risk of major adverse cardiovascular events. The modified Cardiometabolic Disease Staging System predicted 10-year risk of major adverse cardiovascular events, performing superiorly to the Framingham risk score and comparably to the ACC/AHA pooled cohort equations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: